This paper is available online at http://dmd.aspetjournals.org
TY029
1 (Fig. 1) , an N-pyrrolo [1,2-c] imidazolylphenyl sulfonamide herbicide, is a protoporphyrinogen oxygenase inhibitor that controls economically important weeds in cereals, corn, soybeans, and sorghum at low use rates. Although the metabolism of sulfonamides is well described in the literature (Nagwekar and Kundu, 1982) , neither the metabolism nor the kinetics of pyrrolo [1,2-c] imidazole substituents is well reported. In a previous study, we described the metabolism and excretion kinetics of TY029 in rats (Moghaddam et al., 2001 ). The present study was conducted to gain insights into the plasma pharmacokinetics and tissue distribution of TY029 in male and female rats after a single high and low oral dose of this compound. Understanding the tissue distribution and plasma and tissue kinetics of herbicides and their metabolites can help inform the evaluation of health and safety data and their applications to human health risk assessment. Herein, we report a detailed study of total 14 C plasma pharmacokinetic and tissue distribution as well as identification and pharmacokinetics of TY029 and individual plasma metabolites ( Fig.  1 ) as determined by mass spectrometry.
Materials and Methods
Test Substance. TY029 and its metabolites were synthesized by DuPont Crop Protection Products (Wilmington, DE) . Radiolabeled TY029 was synthesized at New England Nuclear and supplied as a white powder. The test substance was stable under the conditions of this study as determined by a lack of change in color and physical state or HPLC purity profile of standards. The chemical purity of the test material was Ͼ99%, whereas its radiochemical and chiral purity was determined to be Ͼ97%.
Animals. Male and nulliparous female Crl:CD(SD)IGS BR rats were obtained from Charles River Laboratories (Raleigh, NC). This rat strain was chosen because it is also the strain used in safety evaluation studies of TY029. At the time of dosing, rats were 7 to 12 weeks of age. All animals weighed 173 to 264 g. Upon arrival, rats were maintained under quarantine for at least 6 days. Animals purchased cannulated were quarantined for at least 2 days. Animal rooms were targeted at a temperature of 23 Ϯ 1°C and a relative humidity of 50 Ϯ 10%. Animal rooms were artificially illuminated (fluorescent light) on a 12-h light/dark cycle. Standard chunk (Certified Rodent LabDiet 5002; PMI Nutrition International, Inc., Richmond, IN) or pelletized rodent chow (Rodent Pellet Certified Formula A/1 Chow; P.J. Noyes Company, Inc., Lancaster, NH) and tap water were provided ad libitum, except during the fasting periods prior to dosing. Chunk chow was given to rats during the quarantine period, and pelletized food or chunk chow was given to rats that were on study.
Dose Concentration and Preparation. Oral dosing was chosen as the route of administration because that is the primary route of human exposure and is required by U.S. Environmental Protection Agency Federal Insecticide, Fungi-cide, and Rodenticide Act and European Union Commission Directives Guidelines. Dosing solutions were prepared in silanized glassware by dissolving the test substance in reagent grade water containing 0.5% methyl cellulose and vortexing until completely dissolved (J. C. Maslanka, personal communications). This solution was used for oral dosing via gavage. Unlabeled TY029 was mixed with [hydantoin-5-14 C]TY029 to achieve the appropriate concentration needed for dosing. Samples of the dosing solutions were analyzed to confirm the purity, concentration, and specific activity. All dose preparation data were recorded on Debra software (version 5.1a; LabLogic, Sheffield, England) . Debra instructions on aliquot preparation were followed during dose preparation, analysis of 14 C concentrations, and radiochemical purity. While stored frozen at Ϫ20°C, dosing solutions were considered usable for up to 2 weeks. Freezer storage stability conducted on 172-day-old samples indicated an absence of degradation at Ϫ20°C.
The total dose volume was targeted at ϳ4 ml/kg. In the low-dose group, rats received a nominal single oral dose of 2 mg/kg of body weight by gavage. About 30 Ci of radioactivity was delivered to each rat. The low dose was chosen to be nontoxic, but expected to be high enough to allow for metabolite identification in excreta and samples containing Ͼ5% of dose. In the high-dose group, rats received a nominal single oral dose of 50 mg/kg of body weight by gavage. Again, about 30 Ci of radioactivity was delivered to each rat. The high dose was selected to approximate the minimal effects observed on the hematopoietic system and nutritional parameters in the rat developmental and subchronic toxicity studies. Metabolite profiling and identification were undertaken at both dose levels using unlabeled TY029.
Animal Dosing and Sample Collection. All dosing solutions were analyzed for chemical and radiochemical purity before dosing as described above.
Plasma pharmacokinetics of total radioactivity. Groups of six male and six female rats were purchased with cannula surgically implanted in the jugular vein. All rats were fasted overnight (15-20 h). Half of the male and half of the female rats received a single 2 mg/kg nominal dose of [hydantoin-5-14 C]TY029 via oral gavage. The second group of rats received a single 50 mg/kg nominal dose of [hydantoin-5-14 C]TY029 via oral gavage. Rats were housed individually in glass metabolism units. Blood samples were collected as described below at approximately 15 and 30 min, 1, 1.5, 2, 4, 6, 8, 12 , and 24 h, and every 24 h thereafter for a total of 168 h (7 days). Plasma samples were prepared as described below and stored at approximately Ϫ20°C until needed.
Plasma pharmacokinetics of nonradiolabeled TY029 and metabolites. For the purpose of plasma metabolite profiling and pharmacokinetics of individual compounds, a group of six male and six female rats were purchased with dmd.aspetjournals.org cannula surgically implanted in the jugular vein. These animals were treated in the same manner as described for those in the total radioactivity pharmacokinetics study except that they were dosed with nonradiolabeled TY029. Blood samples were collected at 15 and 30 min, 1, 2, 4, and 8 h after administration of the oral dose. Plasma samples were prepared as described below and stored at approximately Ϫ20°C until preparation for LC/MS analysis.
Blood collection. Blood (approximately 0.2-0.4 ml) was drawn from the cannula and placed into heparinized tubes for analysis of total radioactivity in plasma and red blood cells. Tail vein blood was collected in instances when the jugular cannula failed to supply blood. Rats were placed into a polyethylene restrainer on a heating pad to increase blood circulation in the extremities before collecting blood from the tail vein. A maximum of 1 ml/100 g of body weight was withdrawn in a 24-h period. An additional 0.5% blood volume based on body weight was withdrawn thereafter, not to exceed a total of 2% of the animal's body weight, as mandated by DuPont Animal Welfare Committee. In addition, animals were given blood transfusions, if needed. The blood transfusion solution was prepared as described in the literature (Waynforth and Fleaknell, 1994) . The influence of blood replacement on plasma kinetics was assumed to be negligible and not taken into account in the analysis. In brief, an acid-citrate-dextrose solution was prepared by diluting 0.5 g of tri-sodium citrate (dihydrate), 0.2 g of citric acid, and 1.2 g of glucose to 25 ml using a saline solution (0.9% aqueous sodium chloride solution). To obtain blood replacement solution, 10 ml of blood from a donor rat was diluted with 1.5 ml of the acid-citrate-dextrose solution and appropriate volumes were transfused into acceptor rats through their jugular vein cannulae.
Tissue distribution at tC max and tC max/2 . Groups of 16 male and 16 female rats were placed in glass metabolism units and fasted overnight. Eight animals from each group were gavaged with a nominal dose of 2 mg/kg and the other eight from each sex group were gavaged with a nominal dose of 50 mg/kg of [hydantoin-5- 14 C]TY029. At the time of maximal blood 14 C concentrations (tC max ), determined for each dose in the total radioactivity pharmacokinetics study (above), four rats from each group were sacrificed by CO 2 asphyxiation.
At the time when the blood concentration of 14 C fell to one-half of C max (tC max/2 ), all of the remaining animals were sacrificed. In all cases, whole blood (plasma and red blood cells), liver, kidney, heart, lung, thyroid, spleen, brain, fat, carcass, testes, ovaries, pituitary, muscle, adrenals, skin, bone (marrow and mineral), GI tract and contents, uterus, and pancreas were collected. All tissues were frozen at approximately Ϫ20°C until processing and analysis.
Terminal plasma and tissue distributions. A group of eight male and eight female rats were dosed with 2 or 50 mg/kg of [hydantoin-5- 14 C]TY029 via oral gavage after fasting overnight. After 96 h (Ͼ90% excretion), rats were terminated and tissues described in the previous section were collected. These samples were stored frozen at approximately Ϫ20°C.
Sample Preparation. The tissue and plasma samples were processed prior to radioactivity counting and metabolite profiling.
Tissues. Solid samples were combusted in sample oxidizers (models 306 and 307; Packard, Meriden, CT) for 1 to 1.5 min while trapping the liberated radioactive CO 2 and volatiles in CarboSorb E (Packard). Radioactivity was then assayed by liquid scintillation counting (Packard).
Plasma. To separate plasma from red blood cells, blood was centrifuged at approximately 4°C for 15 min and 2000g. Plasma was stored at approximately Ϫ20°C. Radioactivity in plasma was quantified by LSC. For LC/MS analysis, a 96-well SPE method (X. Tang, personal communications) was used to extract the compounds of interest from spiked and actual rat plasma samples. In brief, the high-performance extraction disk plate [Octadecyl (C 18 ) SD and 1200 l of polypropylene microtubes in microracks (3M Filtration Products, St. Paul, MN)], placed in a QIAvac manifold system (QIAGEN, Inc., Valencia, CA), was conditioned and washed with 200 l of acetonitrile and then 250 l of 1% formic acid in water. Depending on the level of radioactivity in each plasma sample, 50 to 150 l of plasma was mixed with 250 l of 1% aqueous formic acid in the SPE well and eluted under vacuum. After the wells were washed three times with 200 l of 1% formic acid, the analytes were eluted with 4 ϫ 100 l of acetonitrile. The eluents were dried under nitrogen gas before reconstitution in the appropriate amount of 9:1, water/acetonitrile (with 0.4% formic acid). All reconstituted solutions were transferred to autosampler microvials for LC/MS/MS analysis. Measurement of Radioactivity. Radioactivity was measured using a Packard Tri-CarbLiquid Scintillation Analyzer (model 2500TR series). Samples were counted by LSC for 10 min. Group data were represented as mean Ϯ S.D. Samples with Ͼ10% LSC variability were reanalyzed when possible.
HPLC Method. The primary HPLC method employed a Hewlett-Packard Series 1100 pump (Palo Alto, CA) equipped with a diode array detector and an autosampler. The HPLC method used a Zorbax Rx-C 8 , 2.1 ϫ 150-mm column with 5-m-diameter packing, and a Zorbax analytical guard column, 4.6 ϫ 12.5-mm with 5-m-diameter packing (MAC Mod, Chadds Ford, PA) attached in tandem and maintained at 40°C. The flow rate was 0.3 ml/min with a gradient of 9:1, 0.1% aqueous formic acid/acetonitrile to 100% acetonitrile in 40 min. The injection volume was 40 to 50 l.
Mass Spectrometer Operating Conditions. The LC/MS analysis was carried out in the electrospray negative ion mode with the ion trap LC/MS LCQ (Finnigan, San Jose, CA) system. The electrospray voltage, detector voltage, and capillary temperature were 4.45 V, 900 V, and 230°C, respectively. Mass spectrometry tune files, at optimized conditions, were generated for TY029 and the acidic metabolite 3 (Fig. 1) by infusing a standard solution into the ion source. TY029 and its diastereomeric metabolite 2 had the same molecular ion mass. The same similarity existed between the acidic metabolite 3 and the two alcoholic metabolites 4 and 5, and the two acidic metabolites 6 and 7. Therefore, the tune file for TY029 was used for its diastereomeric metabolite 2. The tune file generated for the acidic metabolite 3 was used for the alcoholic metabolites 4 and 5. The tune file for metabolite 6 was used for both acidic metabolites 6 and 7.
Preparation of standard and fortified plasma solutions. A 1000-ppm stock solution of each standard was prepared by weighing 1 mg of standard on an analytical balance and dissolving with 1 ml of acetonitrile. These solutions were stored in the freezer until use. Standard mixes were prepared by taking the appropriate amount of each stock solution and diluting with the appropriate amount of HPLC grade H 2 O. These solutions were prepared fresh at the beginning of each set of analyses. To produce the fortified samples, 360 l of control plasma was spiked with 40 l of a 5-ppm standard mixture and then extracted as described above in the sample preparation section. This fortification level represented 500 ppb in plasma. As a control, unspiked rat plasma was extracted using the same extraction method. The control sample extract was analyzed using the same LC/MS method to determine whether there was any interference in the selected monitored ion for each analyte at its specific retention time. The level of TY029 and metabolites delivered by the standard solution to generate calibration curves ranged from 0.5 to 60 ng depending on the animal dose group and the dilution factor used for the extracted samples. The method was validated by analyzing a control unfortified plasma extract and a set of fortified plasma samples at 500 ppb with the LC/MS method.
Detector response. The mass spectrum for TY029 and its diastereomeric metabolite 
The m/z value and relative abundance of those ions were used to confirm the identity of the target compounds and increase the method selectivity.
Limit of detection (LOD).
The LOD for TY029 and the five target metabolites were set at the level which yielded an LC/MS selective ion signal with a signal to noise ratio of 5:1.
Statistical and pharmacokinetics calculations. Data were collected and compiled in Debra software (version 5.1a). Data manipulations and statistical calculations (mean Ϯ S.D.) were performed in Excel software (Microsoft, Redmond, WA). Samples with Ͼ10% LSC variability were reanalyzed when possible. For pharmacokinetics calculations, Origin (version 4.1; Microcal Software, Inc., Northampton, MA) and WinNonlin (version 3.2, Pharsight Corp., Mountainview, CA) softwares were used.
Results
Plasma Pharmacokinetics of Total Radioactivity. The objective of this experiment was to determine C max , C max/2 , tC max , tC max/2 , terminal half-life (t 1/2 lambda Z), and AUC INF after a single oral dose of radiolabeled TY029. Figure 2 displays the plasma total 14 C pharmacokinetics after 50 and 2 mg/kg oral doses of radiolabeled test compound as microgram equivalents of TY029 per gram of plasma. In both high-and low-dose female and the low-dose males, the level of radioactivity in plasma fell below detection limits within 12 h after oral exposure to TY029. In high-dose males, such levels were attained within 50 h postdosing. The estimated values for pharmacokinetics parameters are listed in Table 1 .
Plasma Pharmacokinetics of TY029 and Metabolites. The objective of this study was to identify and quantitate individual TY029-related compounds in plasma. Therefore, plasma samples from male and female rats dosed with high and low levels of nonradiolabeled TY029 were analyzed by LC/MS. Each compound (or mixture of isomers) was identified based on its retention time comparison to the synthetic standards and diagnostic LC/MS fragments. Representative plasma LC/MS traces of TY029 and its metabolites for high-dose rats are shown in Fig. 3 . As can be observed, TY029 and its metabolites were detected in plasma after oral dosing of male and female rats in both dose groups (low-dose data not shown). Figure 4 depicts the proposed metabolic pathway for TY029, in male and female rats, as determined by the nature of metabolites in the plasma. For quantitative purposes, plasma samples were studied after SPE clean up and analysis on LC/MS/MS. The average plasma extraction efficiencies were 104.0% for TY029, 91.8% for metabolite 2, 97.0% for metabolite 3, 93.0% for metabolite 4, 88.7% for metabolite 5, and 87.8% for metabolite 6. The LC/MS ion chromatograms for the unfortified sample indicated no mass interferences at any of the target compounds retention times. The LOD was determined to be an average of 100 ppb for TY029, 80 ppb for metabolites 2 and 5, 40 ppb for metabolites 3 and 6, and 20 ppb for metabolite 4. A qualitative analysis of the total ion chromatogram of these samples was performed to examine plasma concentrations of each TY029 related component as a function of time. Plasma concentrations of stereoisomers were summed as each pair of stereoisomers represented the same metabolic event. Because of the low plasma concentration levels of analytes in the low-dose groups, it was difficult to construct meaningful pharmacokinetic plots for individual analytes of interest. However, a cursory observation of the available data (not shown) showed that TY029 and the acidic metabolite 3 appear to be the major compounds present in low-dose male and female plasma. In the high-dose groups, pharmacokinetics analysis of individual compounds of interest (Fig. 5) , demonstrated that in both sexes the acidic metabolite 3 was the predominant metabolite in plasma from 0.25 to 8 h post dosing. While high-dose males exhibited a sharp decline in their plasma concentration of metabolite 3, the females maintained an easily quantifiable concentration for this metabolite, 8 h after exposure. It was evident by examining these data that in the total 14 C PK study, metabolite 3 accounted for the majority
FIG. 3. The LC/MS ion traces of TY029 and metabolites in rat plasma 1 h after a 50 mg/kg oral dose.

FIG. 4. Proposed metabolic pathway for degradation of TY029 as determined by the nature of metabolites in rat plasma.
FIG. 5. Plasma pharmacokinetics of TY029, and its metabolites 0.25 to 8 h after a 50 mg/kg oral dose determined by LC/MS.
PHARMACOKINETICS AND TISSUE DISTRIBUTION OF A HERBICIDE
at ASPET Journals on May 30, 2017 dmd.aspetjournals.org of the radioactivity in female plasma while in the males other compounds contributed to TY029 equivalents significantly. Tissue Distribution at tC max , tC max/2 , and Terminal Time Points. The objective of this study was to determine the tissue concentrations of the parent compound and its metabolites (total radioactivity) at tC max and tC max/2 . Table 2 summarizes the tissue distribution data at tC max for all animal groups. At tC max , the highest percentage of dose resided in the carcass, whole blood, liver, GI tract, and GI contents of all animals (Table 2) , which is consistent with the tissue to plasma ratio (data not shown). The total amount of radioactivity in tissues (GI content discounted) were 48.0 and 59.1% of the dose in the high-dose (male and female, respectively), and 32.7 and 55.5% of the dose in the low-dose groups (male and female, respectively). Table 3 summarizes the tissue distribution data at tC max/2 for all animal groups. In general, the total tissue radioactivity declined in the females of both dose groups at C max/2 . Such declines were not observed in the male rats of either dose groups. The tissues with highest concentration of the dose remained the same as the ones at tC max in all dose groups. Table 4 provides data on tissue distribution of radioactivity 96 h after the oral dose. The overall tissue accumulation of radioactivity in any group at this time point was less than 0.5% of the dose.
Discussion
TY029 is an experimental herbicide. As partial satisfaction of regulatory requirements to establish safety of TY029 (EPA, 1998), PK and tissue distribution studies were carried out. Figure 2 depicts data for the overall plasma PK of total radioactivity in all animals. These data demonstrates a sharp decline in total radioactivity in the plasma after oral administration of [ 14 C]TY029. As summarized in Table 1 , within each dose group there were no significant differences for the C max between male and female rats within each dose group. However, it took slightly longer for males to reach C max (tC max ) within each dose group. Although there did not appear to be a significant sex difference in C max/2 , the high-dose males took longer to reach C max/2 (tC max/2 ) than the high-dose females. There also did not appear to be a significant sex difference in the low-dose rats regarding these parameters. In addition, there were no significant sex differences in the terminal half-lives of the high or low-dose rats (Table 1) . Closer examination of Fig. 2 suggested a longer elimination time for the high single dose males compared with the females in the same dose group. In both dose groups, males had a higher AUC INF than the females (Table 1) . This trend may indicate a slightly slower rate of elimination for male rats based solely on total 14 C plasma pharmacokinetics data. Other observations supporting this conclusion are, first, the rise and decline of plasma 14 C concentrations in the high-dose females was considerably sharper than that of males in the same dose group (Fig. 2) . Second, the total tissue concentration of radioactivity in females was always higher than that of males at tC max , but it fell to levels below that of males by tC max/2 (Fig. 6) . Third, females eliminated significantly more radioactivity in their urine than males in the first 12 h (Moghaddam et al., 2001) .
Interestingly, by comparing Tables 2, 3 , and 4, it could be concluded that in the high-dose animals, the majority of the radioactivity at all three time points is found in the same tissues with varying ratios. At tC max the tissue concentrations of total 14 C were concentrated in the carcass, whole blood, liver, kidney, GI tract, GI contents, and the plasma. In both high-dose groups, GI contents contained most of the radioactivity. At tC max/2 , the level of radioactivity in all samples (with the exception of GI contents) had subsided drastically (Table 3) . By 96 h after oral dose (Table 4) , all samples including GI content accounted for extremely low residues. The low-dose animals exhibited the same general trends with the exception that the liver contained (Tables 2-4) . A plot of levels of radioactivity in the GI tract contents for each dose group at tC max , tC max/2 , and the terminal time points were constructed (Fig. 6 ). These data indicated that the high-dose animals seemed to exhibit biliary excretion supported by the fact that at tC max/2 more radioactivity is present in the GI tract than at tC max . Biliary excretion was not evident in the low-dose animals.
To analyze rat plasma for the parent compound and the individual metabolites in rat plasma, an electrospray ion trap LC/MS method was developed due to its selectivity and sensitivity. Because detection of metabolites relied on LC/MS, the use of radiolabeled TY029 was not necessary. The negative ion ionization mode was found to be more sensitive than the positive ion mode for TY029 and the five targeted metabolites. This technique offered a sufficient separation of the target compounds in 30 min and selective detection of each compound after minimal sample clean up using the 96-well miniature solid phase extraction technique. After validation of this technique for detection of the above compounds, rat plasma samples were analyzed. Within each dose and sex group, plasma samples collected at each time point were prepooled before submission for MS. Quality control samples of the standard mixture of the six TY029 analytes, the plasma extract, and control plasma were analyzed at the beginning and at the end of each sample set to determine the instrument performance. The method detection limits were 40 to 100 ppb depending on the metabolite detected. The extraction efficiency was determined by analyzing fortified control plasma samples at 500 ppb. The average recovery was determined to be 87 to 103% for TY029 and metabolites, which was satisfactory from a regulatory standpoint.
As expected, the control plasma was devoid of any TY029-related compounds. Qualitative mass spectral analyses of plasma samples revealed the identity of metabolites in circulation. The overall metabolite profile in the plasma (Fig. 3) was consistent with the metabolite profile reported in the excreta (Moghaddam et al., 2001) . Figure 4 summarizes the proposed metabolic pathway corresponding to the metabolites found in the plasma of both sexes. As can be seen, TY029 can undergo epimerization to its diastereomer (2). This represented a minor metabolic route. Alternatively, TY029 can undergo a hydrolytic cleavage of an amide bond in the hydantoin ring and give rise to the acidic metabolite 3. A bond cleavage in the pyrrolidine ring can result in the alcohols 4 and 5 and they in turn can undergo further oxidative metabolism to the acids 6 and 7.
Quantitative mass spectral analysis of individual TY029 components in plasma is represented in Fig. 5 . As shown, the acidic metabolite 3 was the predominant plasma metabolite in both sexes. However, the pathway leading to the biosynthesis of this metabolite was more prevalent in the females than the male rats of the high-dose group (Fig. 5) . Conversely, the pathway leading to oxidative metabolism of the pyrrolidine ring into alcohols and the subsequent acids seemed more active in the males than in the females of the high-dose group. We were not able to construct analogous PK plot for the low-dose rats. This was due to extremely low concentrations of analytes in the low-dose plasma.
In conclusion, TY029 and its metabolites were eliminated from the animals within 96 h of oral dosing, and tissue sequestration was not observed. The plasma metabolite profile of TY029 was consistent with that of excreta. Acidic metabolite 3 was the major metabolite observed in the plasma of all animals tested. In high-dose rats, data are suggestive of biliary excretion when examining the total 14 C data. In a related study (C. A. Maxwell, E. G. Esrey, and A. M. Brown, personal communication), rat metabolites (2-7) were tested for protoporphyrinogen oxidase inhibition and found to be less potent inhib- itors than TY029. The biggest reduction in potency (Ն3 orders of magnitude) resulted when either of the pyrrolidine or hydantoin rings were opened (i.e., the acid or alcohol metabolites). The diastereomeric metabolite (2) was approximately 50-fold less active than TY029.
These observations indicated the importance of intact rings for maximal PPO inhibition activity. They also implied that the minimal change in the 3-dimentional structure of this hydantoin ring can also significantly reduce activity. Therefore, the proposed metabolic pathway would be consistent with a detoxification process.
